Q4 2025 · 13F-HR
NEXTBio Capital Management LPholdings as filed
Filed 2026-02-13 · accession 0001172661-26-000761
$170.5M
Reported value
23
Positions
2025-12-31
Period end
The Brief · NEXTBio Capital Management LP · Q4 2025
AI · grounded in 13F
NEXTBio Capital Management LP established a new position in Terns Pharmaceuticals Inc 430 valued at $22.27M. The fund also initiated new stakes in Protagonist Therapeutics Inc PTGX for $20.05M and Vor Biopharma Inc VOR for $13.08M. Additional new positions include Zenas Biopharma Inc ZBIO and Shattuck Labs Inc STTK.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $22.3M | 13.1% | 551,190 | Common | NONE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $20.1M | 11.8% | 229,619 | Common | NONE |
| 929033207 | VOR | VOR BIOPHARMA INC | $13.1M | 7.67% | 999,967 | Common | NONE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $11.7M | 6.86% | 321,983 | Common | NONE |
| 82024L103 | STTK | SHATTUCK LABS INC | $11.5M | 6.74% | 3,149,907 | Common | NONE |
| 92337C203 | VSTM | VERASTEM INC | $10.1M | 5.92% | 1,307,330 | Common | NONE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $8.7M | 5.08% | 82,686 | Common | NONE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $8.2M | 4.83% | 183,704 | Common | NONE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $7.2M | 4.24% | 67,586 | Common | NONE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $6.6M | 3.85% | 94,443 | Common | NONE |
| 46124U107 | IVA | INVENTIVA SA | $6.0M | 3.54% | 1,298,701 | Common | NONE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $6.0M | 3.51% | 1,114,005 | Common | NONE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $5.2M | 3.05% | 752,631 | Common | NONE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $5.0M | 2.95% | 615,720 | Common | NONE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $4.4M | 2.59% | 372,856 | Common | NONE |
| 92243G108 | PCVX | VAXCYTE INC | $4.4M | 2.58% | 95,485 | Common | NONE |
| 30054Y107 | EVMN | EVOMMUNE INC | $3.9M | 2.29% | 228,286 | Common | NONE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $3.4M | 2.00% | 95,819 | Common | NONE |
| 254604101 | IRON | DISC MEDICINE INC | $3.4M | 1.99% | 42,778 | Common | NONE |
| H5870P102 | OCS | OCULIS HOLDING AG | $3.0M | 1.75% | 149,750 | Common | NONE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $2.9M | 1.69% | 163,362 | Common | NONE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $2.1M | 1.25% | 131,796 | Common | NONE |
| 007002207 | ACET | ADICET BIO INC | $1.3M | 0.78% | 157,827 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.